Your browser is no longer supported. Please, upgrade your browser.
Settings
SELB [NASD]
Selecta Biosciences, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own7.20% Shs Outstand110.74M Perf Week0.00%
Market Cap380.29M Forward P/E- EPS next Y-0.45 Insider Trans147.46% Shs Float80.56M Perf Month-17.22%
Income-73.90M PEG- EPS next Q-0.12 Inst Own50.00% Short Float8.53% Perf Quarter15.33%
Sales27.60M P/S13.78 EPS this Y44.00% Inst Trans-0.05% Short Ratio5.66 Perf Half Y-13.50%
Book/sh-0.18 P/B- EPS next Y15.10% ROA-49.40% Target Price- Perf Year35.69%
Cash/sh1.34 P/C2.57 EPS next 5Y- ROE509.20% 52W Range1.47 - 5.70 Perf YTD14.19%
Dividend- P/FCF11.28 EPS past 5Y29.40% ROI-842.40% 52W High-39.30% Beta0.98
Dividend %- Quick Ratio1.90 Sales past 5Y22.50% Gross Margin- 52W Low135.36% ATR0.23
Employees43 Current Ratio1.90 Sales Q/Q- Oper. Margin- RSI (14)39.12 Volatility7.30% 6.23%
OptionableYes Debt/Eq- EPS Q/Q-7.20% Profit Margin- Rel Volume0.38 Prev Close3.59
ShortableYes LT Debt/Eq- EarningsMay 13 BMO Payout- Avg Volume1.21M Price3.46
Recom1.70 SMA20-8.39% SMA50-16.54% SMA200-7.57% Volume458,567 Change-3.62%
Jun-15-21Initiated BTIG Research Buy $10
Jan-26-21Upgrade Mizuho Neutral → Buy $2.50 → $8
Oct-01-20Downgrade William Blair Outperform → Mkt Perform
Oct-01-20Downgrade Mizuho Buy → Neutral $2.50
Jun-12-20Downgrade Stifel Buy → Hold
Apr-28-20Initiated H.C. Wainwright Buy $8
Jan-29-20Initiated Cantor Fitzgerald Overweight $10
Jan-21-20Initiated William Blair Outperform
Jun-27-18Initiated Janney Buy $33
Mar-30-17Reiterated UBS Buy $26
Jul-27-21 10:36AM  
Jul-26-21 08:00AM  
Jul-14-21 10:55AM  
Jul-08-21 08:00AM  
Jun-24-21 08:00AM  
Jun-16-21 08:00AM  
Jun-14-21 08:00AM  
Jun-12-21 05:46AM  
Jun-01-21 08:00AM  
May-25-21 08:00AM  
May-14-21 07:10AM  
May-13-21 12:11PM  
08:00AM  
06:30AM  
May-12-21 07:05AM  
May-06-21 08:00AM  
Apr-29-21 04:15PM  
01:06PM  
10:52AM  
08:30AM  
Apr-05-21 08:00AM  
Mar-13-21 02:39AM  
Mar-11-21 09:25AM  
08:00AM  
05:30AM  
Mar-04-21 12:30PM  
08:00AM  
Mar-01-21 08:00AM  
Feb-24-21 04:15PM  
Feb-22-21 05:11AM  
Feb-17-21 08:00AM  
Feb-16-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 08:00AM  
Dec-21-20 11:45PM  
Dec-16-20 02:16PM  
Nov-20-20 12:09PM  
Nov-19-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 08:42AM  
Nov-06-20 11:31PM  
Nov-05-20 10:14AM  
07:30AM  
Oct-29-20 08:00AM  
Oct-27-20 12:35PM  
07:00AM  
Oct-26-20 07:09AM  
Oct-21-20 11:58AM  
10:46AM  
Oct-20-20 08:00AM  
Oct-13-20 12:25PM  
Oct-10-20 10:20AM  
Oct-09-20 07:20AM  
Oct-08-20 04:05PM  
Oct-01-20 04:38PM  
Sep-30-20 04:15PM  
Sep-24-20 04:17PM  
Sep-23-20 07:00AM  
Sep-08-20 08:00AM  
Sep-01-20 08:00AM  
Aug-28-20 03:38PM  
Aug-06-20 10:45AM  
10:36AM  
07:30AM  
Aug-04-20 12:47PM  
Aug-03-20 04:05PM  
12:49PM  
08:15AM  
Jul-30-20 08:00AM  
Jul-28-20 06:00AM  
Jul-23-20 11:30AM  
Jul-15-20 07:11AM  
Jun-23-20 04:05PM  
Jun-19-20 12:22PM  
08:49AM  
Jun-18-20 08:30AM  
Jun-16-20 11:30AM  
Jun-15-20 08:00AM  
Jun-12-20 12:24PM  
Jun-11-20 05:15PM  
May-29-20 08:52AM  
May-26-20 08:00AM  
May-20-20 01:06PM  
May-18-20 10:04AM  
May-12-20 12:49PM  
May-08-20 02:30PM  
May-07-20 07:30AM  
May-06-20 12:04PM  
May-05-20 08:00AM  
Apr-30-20 08:00AM  
Apr-28-20 08:00AM  
Apr-07-20 08:00AM  
Mar-31-20 08:12AM  
Mar-12-20 08:00AM  
Mar-05-20 08:00AM  
Mar-03-20 03:00PM  
Feb-23-20 07:10AM  
Feb-18-20 08:00AM  
Dec-19-19 08:25AM  
08:15AM  
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brunn CarstenPresident and CEOJun 02Sale4.384,80621,041222,958Jun 03 04:30 PM
Brunn CarstenPresident and CEOJun 01Option Exercise0.0010,9380227,764Jun 03 04:30 PM
TRABER PETER GChief Medical OfficerMay 26Buy3.9920,00079,850135,500May 27 06:00 PM
SPRINGER TIMOTHY ADirectorMay 26Buy4.00926,1703,705,69919,154,427May 26 05:21 PM
TRABER PETER GChief Medical OfficerMay 25Buy3.485,00017,400115,500May 26 04:33 PM
SPRINGER TIMOTHY ADirectorMay 25Buy3.55383,8301,362,09818,228,257May 26 05:21 PM
SPRINGER TIMOTHY ADirectorMay 24Buy3.38590,0001,992,07617,844,427May 26 05:21 PM
TRABER PETER GChief Medical OfficerMay 24Buy3.3212,50041,498110,500May 26 04:33 PM
SPRINGER TIMOTHY ADirectorMay 21Buy3.192,773,4798,847,39817,254,427May 25 04:27 PM
Kishimoto Takashi KeiChief Scientific OfficerMay 07Option Exercise2.7713,62937,752177,778May 11 04:24 PM
BARABE TIMOTHY CDirectorMar 26Buy4.1010,00041,000181,013Mar 30 04:50 PM
TRABER PETER GChief Medical OfficerMar 18Buy4.5010,00045,00098,000Mar 19 05:34 PM
TRABER PETER GChief Medical OfficerMar 17Buy4.5310,00045,29588,000Mar 19 05:34 PM
Johnston Lloyd P.COO and SVP, R&DMar 17Sale4.4515,12867,31287,477Mar 19 05:33 PM
Brunn CarstenPresident and CEOMar 02Sale4.265,46123,257216,826Mar 03 05:21 PM
Brunn CarstenPresident and CEOMar 01Option Exercise0.0010,9370222,287Mar 03 05:21 PM
Johnston Lloyd P.COO and SVP, R&DFeb 11Option Exercise0.6344,87128,269102,605Feb 16 06:10 PM
TRABER PETER GChief Medical OfficerDec 14Buy3.2440,000129,42440,000Dec 16 04:31 PM
Brunn CarstenPresident and CEODec 02Sale3.353,32311,134101,350Dec 03 04:22 PM
Brunn CarstenPresident and CEODec 01Option Exercise0.0010,9380104,673Dec 03 04:22 PM
Kishimoto Takashi KeiChief Scientific OfficerOct 23Option Exercise2.7730,00083,100126,149Oct 27 05:13 PM
SPRINGER TIMOTHY ADirectorOct 23Buy2.71994,4882,699,73714,480,948Oct 23 05:12 PM
SPRINGER TIMOTHY ADirectorOct 22Buy2.631,770,2044,656,69913,486,460Oct 23 05:12 PM
SPRINGER TIMOTHY ADirectorOct 21Buy2.50880,0002,199,47211,716,256Oct 23 05:12 PM
SPRINGER TIMOTHY ADirectorOct 20Buy2.21910,0002,013,19310,836,256Oct 20 06:07 PM
SPRINGER TIMOTHY ADirectorOct 19Buy2.36759,5001,795,0029,926,256Oct 20 06:07 PM
SPRINGER TIMOTHY ADirectorOct 16Buy2.42218,196528,0349,166,756Oct 20 06:07 PM
SPRINGER TIMOTHY ADirectorOct 09Buy2.00276,703552,4658,948,560Oct 14 04:18 PM
SPRINGER TIMOTHY ADirectorOct 08Buy1.89530,4411,000,8368,671,857Oct 08 05:50 PM
SPRINGER TIMOTHY ADirectorOct 07Buy1.65654,9531,078,5778,141,416Oct 08 05:50 PM
SPRINGER TIMOTHY ADirectorOct 06Buy1.682,000,0003,365,8007,486,463Oct 08 05:50 PM
BARABE TIMOTHY CDirectorOct 06Buy1.6850,00083,985171,013Oct 08 04:25 PM
Brunn CarstenPresident and CEOSep 02Sale2.393,3648,03593,735Sep 03 04:29 PM
Brunn CarstenPresident and CEOSep 01Option Exercise0.0010,937097,099Sep 03 04:29 PM